

# Brian L Vanderbeek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9552442/publications.pdf>

Version: 2024-02-01

62  
papers

1,516  
citations

430442

18  
h-index

329751

37  
g-index

62  
all docs

62  
docs citations

62  
times ranked

2130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. British Journal of Ophthalmology, 2023, 107, 215-220.	2.1	18
2	Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. British Journal of Ophthalmology, 2022, 106, 87-90.	2.1	7
3	Association of metformin and development of dry age-related macular degeneration in a U.S. insurance claims database. European Journal of Ophthalmology, 2022, 32, 417-423.	0.7	12
4	Risk of Non-infectious Uveitis with Metformin Therapy in a Large Healthcare Claims Database. Ocular Immunology and Inflammation, 2022, 30, 1334-1340.	1.0	2
5	Hypercoagulability Testing and Hypercoagulable Disorders in Young Central Retinal Vein Occlusion Patients. Ophthalmology Retina, 2022, 6, 37-42.	1.2	4
6	The association of stroke with central and branch retinal arterial occlusion. Eye, 2022, 36, 835-843.	1.1	10
7	Fibroblast Growth Factor Receptor Inhibitor-associated Multifocal Serous Retinal Detachments: A Case Report. Journal of Vitreoretinal Diseases, 2022, 6, 337-340.	0.2	2
8	Board Certification Is Associated With a Reduced Risk of Endophthalmitis After Intravitreal Injections. Journal of Vitreoretinal Diseases, 2022, 6, 116-121.	0.2	2
9	Recent Practice Patterns in Acute Retinal Artery Occlusions in the United States. Ophthalmic Epidemiology, 2022, , 1-7.	0.8	0
10	Challenges in Elucidating Ophthalmology's Standards of Care. JAMA Ophthalmology, 2022, , .	1.4	1
11	Statin use and the risk of progression to vision threatening diabetic retinopathy. Pharmacoepidemiology and Drug Safety, 2022, 31, 652-660.	0.9	3
12	Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. JAMA Ophthalmology, 2022, 140, 529.	1.4	16
13	Phase 4 Studies on Phosphodiesterase 5 Inhibitors. JAMA Ophthalmology, 2022, 140, 484.	1.4	1
14	Visit adherence and visual acuity outcomes in patients with diabetic macular edema: a secondary analysis of DRCRnet Protocol T. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1419-1425.	1.0	10
15	Association of Retinal Vascular Occlusion With Women Filling a Prescription for Female Hormone Therapy. JAMA Ophthalmology, 2021, 139, 42.	1.4	3
16	Angiotensin Converting Enzyme-Inhibitors and Incidence of Non-infectious Uveitis in a Large Healthcare Claims Database. Ophthalmic Epidemiology, 2021, , 1-6.	0.8	0
17	Curtailing Opioid Overprescribing in Ophthalmology. JAMA Ophthalmology, 2021, 139, 162.	1.4	1
18	Certification and Credentials of Intravitreal Injection Proceduralists in the United States. Ophthalmology Retina, 2021, 5, 487-489.	1.2	5

#	ARTICLE	IF	CITATIONS
19	Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 2783-2793.	1.0	0
20	SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , 2021, 41, 1455-1462.	1.0	6
21	Demographic and Clinical Characteristics Associated with Minimally Invasive Glaucoma Surgery Use. <i>Ophthalmology</i> , 2021, 128, 1292-1299.	2.5	19
22	Telemedicine and the Exacerbation of Health Care Disparities. <i>JAMA Ophthalmology</i> , 2021, 139, 1182.	1.4	17
23	Predictive factors for patients receiving intravitreal anti-vascular endothelial growth factor for the treatment of diabetic macular edema. <i>European Journal of Ophthalmology</i> , 2020, 30, 72-80.	0.7	3
24	Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy. <i>Eye</i> , 2020, 34, 934-941.	1.1	16
25	Determinants in Initial Treatment Choice for Diabetic Macular Edema. <i>Ophthalmology Retina</i> , 2020, 4, 41-48.	1.2	7
26	Re: Ludwig et al.: Pentosan polysulfate sodium exposure and drug-induced maculopathy in commercially insured patients in the United States ( <i>Ophthalmology</i> . 2020;127:535-543). <i>Ophthalmology</i> , 2020, 127, e35-e36.	2.5	5
27	ASSOCIATION OF DIAGNOSIS CODE-BASED AND LABORATORY RESULTS-BASED KIDNEY FUNCTION WITH DEVELOPMENT OF VISION THREATENING DIABETIC RETINOPATHY. <i>Ophthalmic Epidemiology</i> , 2020, 27, 498-503.	0.8	3
28	Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2020, 138, 237.	1.4	40
29	Risk of Noninfectious Uveitis with Female Hormonal Therapy in a Large Healthcare Claims Database. <i>Ophthalmology</i> , 2020, 127, 1558-1566.	2.5	5
30	Association of Opioids With Incisional Ocular Surgery. <i>JAMA Ophthalmology</i> , 2019, 137, 1283.	1.4	20
31	COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB. <i>Retina</i> , 2019, 39, 2004-2011.	1.0	29
32	Repeated intravitreal injections of anti-vascular endothelial growth factors and risk of intraocular pressure medication use. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 1931-1939.	1.0	16
33	Adherence to Clinical Trial Supported Evaluation of Optic Neuritis. <i>Ophthalmic Epidemiology</i> , 2019, 26, 321-328.	0.8	2
34	Blindness and Visual Impairment in the Medicare Population: Disparities and Association with Hip Fracture and Neuropsychiatric Outcomes. <i>Ophthalmic Epidemiology</i> , 2019, 26, 279-285.	0.8	30
35	Techniques for improving ophthalmic studies performed on administrative databases. <i>Ophthalmic Epidemiology</i> , 2019, 26, 147-149.	0.8	8
36	The Argument for Sterile Loading of All Intravitreal Injections and the Benefit of Replicated Results. <i>JAMA Ophthalmology</i> , 2019, 137, 343.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Comparative Effectiveness of Generic Latanoprost Versus Branded Prostaglandin Analogs for Primary Open Angle Glaucoma. <i>Ophthalmic Epidemiology</i> , 2019, 26, 63-71.	0.8	6
38	SYSTEMIC BETA-BLOCKERS AND RISK OF PROGRESSION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2019, 39, 918-925.	1.0	11
39	Association of Hypovitaminosis D With Increased Risk of Uveitis in a Large Health Care Claims Database. <i>JAMA Ophthalmology</i> , 2018, 136, 548.	1.4	17
40	Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding. <i>JAMA Ophthalmology</i> , 2018, 136, 122.	1.4	14
41	TESTOSTERONE SUPPLEMENTATION AND RETINAL VASCULAR DISEASE. <i>Retina</i> , 2018, 38, 2247-2252.	1.0	5
42	Revision Surgery After Dacryocystorhinostomy in a National Cohort. <i>JAMA Ophthalmology</i> , 2018, 136, 94.	1.4	1
43	Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. <i>American Journal of Ophthalmology</i> , 2017, 176, 194-202.	1.7	28
44	Diabetic Retinopathy: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 412-418.	4.3	596
45	Accuracy of Billing Codes Used in the Therapeutic Care of Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2017, 135, 791.	1.4	26
46	Re: Yeung et al.: $\beta$ -blockers and neovascular age-related macular degeneration ( <i>Ophthalmology</i> )	2.5	1
47	Automated Segmentation of the Choroid in $\widehat{\text{EDI}}$ -OCT Images with Retinal Pathology Using Convolution Neural Networks. <i>Lecture Notes in Computer Science</i> , 2017, 10554, 177-184.	1.0	26
48	SYSTEMIC BETA-BLOCKERS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2017, 37, 41-46.	1.0	11
49	Trends in the Care of Diabetic Macular Edema: Analysis of a National Cohort. <i>PLoS ONE</i> , 2016, 11, e0149450.	1.1	30
50	Oral Fluoroquinolones, Retinal Detachments, and Claims Database Studies. <i>JAMA Ophthalmology</i> , 2016, 134, 422.	1.4	6
51	Oral Fluoroquinolones and the Risk of Uveitis. <i>JAMA Ophthalmology</i> , 2016, 134, 38.	1.4	23
52	Correspondence. <i>Retina</i> , 2015, 35, e40-e42.	1.0	0
53	The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates. <i>Ophthalmology</i> , 2015, 122, 2311-2315.e1.	2.5	74
54	Association of Compounded Bevacizumab With Postinjection Endophthalmitis. <i>JAMA Ophthalmology</i> , 2015, 133, 1159.	1.4	51

#	ARTICLE	IF	CITATIONS
55	Additional Considerations in the Utility of Dark Adaptometry for the Diagnosis of Age-Related Macular Degeneration. , 2014, 55, 3148.		2
56	A Novel Method for the Measurement of Reflux from Intravitreal Injections: Data from 20 Porcine Eyes. Current Eye Research, 2014, 39, 752-757.	0.7	12
57	Outcomes, Impact on Management, and Costs of Fungal Eye Disease Consults in a Tertiary Care Setting. Ophthalmology, 2014, 121, 2334-2339.	2.5	25
58	Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study. Pharmacoepidemiology and Drug Safety, 2014, 23, 745-752.	0.9	20
59	VOLUME AND COMPOSITION OF REFLUX AFTER INTRAVITREAL INJECTION. Retina, 2014, 34, 1473-1476.	1.0	21
60	ROLE OF STATINS IN THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION. Retina, 2013, 33, 414-422.	1.0	39
61	The Diversity of Traction Mechanisms in Myopic Traction Maculopathy. American Journal of Ophthalmology, 2012, 153, 93-102.	1.7	79
62	Racial Differences in Age-Related Macular Degeneration Rates in the United States: A Longitudinal Analysis of a Managed Care Network. American Journal of Ophthalmology, 2011, 152, 273-282.e3.	1.7	63